Abstract-We reviewed 6 recent outcome trials of blood pressure (BP)-lowering drugs in 74 524 randomized hypertensive or high-risk patients. Over interpretation of nonsignificant or marginal probability values in large trials with overlapping end points, exclusion of patients not tolerating or not adhering to experimental treatments, labeling nonsignificant treatment effects as modest, and insufficient information on the quality of the BP measurements or on the BP changes early after randomization raise concern. From a clinical viewpoint, results should not be extrapolated to patients with characteristics dissimilar from those randomized. The benefit beyond BP lowering in cardiovascular prevention is tiny. Dual inhibition of the renin system should only be used in patients at high risk, in whom all drug combinations have been tried and who cannot be controlled by a single renin system inhibitor. Current evidence does not support BP lowering in normotensive patients or the use of renin system inhibitors for prevention of stroke recurrence. Because angiotensin-receptor blockers might offer less protection against myocardial infarction than angiotensin-converting enzyme inhibitors, the latter should remain the preferred renin system inhibitor for cardiovascular prevention in angiotensin-converting enzyme inhibitor-tolerant patients. In 2 trials, in which new-onset diabetes was a predefined end point, 1000 patients had to be treated for 1 year with an angiotensin-receptor blocker instead of placebo to prevent just 2 cases. From a design viewpoint, the time has come to revise the concept of large simple trials and to pursue research questions that serve patient interests more than showing noninferiority or highlight the ancillary qualities of marketable antihypertensive drugs. (Hypertension. 2010;55:819-831.)
T he Heart Outcomes Prevention Evaluation (HOPE) 1 and the Losartan Intervention for Endpoint Reduction 2 studies were forerunners of a new breed of randomized clinical trials in hypertension. They introduced the concept of a large simple trial 3 and replaced the previous generation of placebocontrolled trials, which had identified new indications for blood pressure-lowering treatment, such as hypertension in older patients from 60 to 80 years of age. 4 -7 Most of the large simple trials investigated blockade of the renin system as a way to prevent cardiovascular complications. The purpose of this article was to review recently published outcome trials in hypertensive or high-risk patients, 8 -27 and to assess their clinical applicability and their implications for the design of future trials. Our review does not include studies on the basis of posttrial monitoring, 28 trials with exclusively microvascular end points, 29, 30 or trials with intermediate or surrogate end points, such as blood pressure, 31 brain natriuretic hormone in plasma, 32 left ventricular mass, 33 or the urinary albumin:creatinine ratio. 34 Table 1 summarizes the characteristics of the 6 reviewed trials, in which 74 524 patients were randomly assigned (range: 3845 16 -19 to 25,620 20 -22 ). The Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) 20 -22 and the Telmisartan Randomized Assessment Study in Angiotensin-Converting Enzyme (ACE) Intolerant Subjects With Cardiovascular Disease (TRANSCEND) 20, 27 were not running independently from each other but have to be viewed as 2 complementary studies within a single research program. 20 The primary objectives of ONTARGET 20 -22 were to determine whether the combination of the angiotensin receptor blocker (ARB) telmisartan plus the ACE inhibitor ramipril was more effective in the prevention of cardiovascular and renal complications than ramipril alone and to test whether telmisartan was at least as effective as ramipril. This explains the dual entries for ONTARGET in Table 1 . The online Data Supplement available at http://hyper.ahajournals.org provides detailed information on the research questions, methods, end points, and outcome results of the 6 reviewed trials over and beyond the information in Table 1 and the evidence reviewed below.
Review of the Evidence

Hypertension in the Very Elderly Trial
The Hypertension in the Very Elderly Trial (HYVET) 16 -19 was not a large simple trial but a primary prevention study, set up with the goal to extend the indication for blood pressure-lowering treatment to very elderly hypertensive patients (Ն80 years). Antihypertensive treatment reduced the incidence of fatal combined with nonfatal stroke by 30%, fatal stroke by 39%, all-cause mortality by 21%, cardiovascular mortality by 23%, and heart failure by 64%. HYVET definitely dispelled the suspicion, on the basis of the pilot trial 16 and a meta-analysis, 35 that the benefit of antihypertensive treatment in the very elderly in terms of stroke prevention might come at the cost of a higher mortality. When generalizing the HYVET results, clinicians should realize that only 11.8% of HYVET patients had a history of cardiovascular disease; that frail elderly were excluded; that it took 6 years to recruit patients, mainly from Eastern Europe (55.8%) and China (39.7%); and that the median follow-up was only 1.8 years. Thus, whether to initiate antihypertensive treatment in the very elderly still remains a matter of sound clinical judgment. To prevent 1 death or 1 stroke, 40 and 94 very elderly subjects had to be treated for 2 years. 18 These numbers might be an overestimate, given the low rate of stroke, although 94 is still an acceptable number in the context of prevention.
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension Trial
European and American guidelines 36, 37 propose single-pill combinations of antihypertensive drugs as an option to initiate antihypertensive treatment. Whether thiazide diuretics should be included in the combination 37 remains controversial. The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) Trial 8 -12 tested whether treatment with the combination of an ACE inhibitor and a dihydropyridine calcium-channel blocker (CCB) would be more effective in reducing cardiovascular events than treatment with an ACE inhibitor plus a thiazide. There were 552 primary-outcome events in the benazepril-amlodipine group (9.6%) and 679 in the benazepril-hydrochlorothiazide group (11.8%), representing a relative risk reduction with benazepril-amlodipine therapy of 19.6% (PϽ0.001) but an absolute risk reduction of only 2.2%. Over the whole duration of the ACCOMPLISH Trial, blood pressure was, on average, 0.9 mm Hg systolic and 1.1 mm Hg diastolic lower (PϽ0.001) on the combination with amlodipine. Nevertheless, the ACCOMPLISH investigators proposed benefit "beyond blood pressure lowering." None of the ACCOMPLISH reports 8 -12 provided precise information on the blood pressure course during the first 6 months after randomization, when study medications were up-titrated. Blood pressure gradients early in a trial produce Kaplan-Meier estimates that separate soon after randomization and result in persistent benefit for the group with the lower blood pressure, even if subsequent levels are similar across randomized groups. 38 Other caveats are the dose 39 and the duration of action 40 of hydrochlorothiazide. At 12.5 to 25.0 mg/d, hydrochlorothiazide has only half of the blood HCTZ indicates hydrochlorothiazide; RRR, relative risk reduction; SBP/DBP, systolic/diastolic blood pressure; …, the information was unavailable in published reports. End points: A indicates hospitalized angina pectoris; CVM, cardiovascular mortality; FS, fatal stroke; HF, hospitalized heart failure; MI, nonfatal myocardial infarction; MICVE, microvascular events; S, nonfatal stroke; RCA, resuscitated cardiac arrest. Major MICVE in ADVANCE were new or worsening nephropathy (development of macroalbuminuria (Ͼ300 mg/g of creatinine), doubling of serum creatinine to a level of Ն2.26 mg/dL (200 mol/L), need for renal replacement therapy, or death because of renal disease) or retinopathy (development of proliferative retinopathy, macular edema, diabetes-related blindness, or retinal photocoagulation therapy). Conversion factors: to convert values of serum creatinine to micromoles per liter, multiply by 88.4; to convert values of blood glucose to millimoles per liter, multiply by 0.05551; to convert values of serum total cholesterol to millimoles per liter, multiply by 0.02586.
*Data show a 1-sided P value to test noninferiority (telmisartan vs ramipril) and a 2-sided P value to test superiority (telmisartan plus ramipril vs ramipril alone). †All but 43 ONTARGET patients were followed up until the end of study or until a primary event. ‡Data show withdrawals among 14 842 patients at the 2-year follow-up visit. §A plus sign indicates combination therapy and a backward slash addition of a second study drug. ʈData show the baseline-adjusted difference in the on-treatment blood pressure (reference minus intervention group). ¶Data include transient ischemic attack. #Definition of renal disease is as follows: ACCOMPLISH, serum creatinine Ͼ1.5 mg/dL (133 mol/L) in women or Ͼ1.7 mg/dL (150 mol/L in men) or presence of macroalbuminuria (Ͼ300 mg/g of creatinine or in the presence of an ACE inhibitor or aldosterone receptor blocker Ͼ200 mg/g of creatinine); ADVANCE, macroalbuminuria (Ͼ300 mg/g of creatinine) or microalbuminuria (30 to 300 mg/g of creatinine); ONTARGET, PRoFESS, and TRANSCEND, microalbuminuria (30 to 300 mg/g of creatinine).
pressure-lowering potency of chlorthalidone. 39 The daily dose of chlorthalidone in the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial, 41 was 12.5 to 25.0 mg, which would correspond with 25.0 to 50.0 mg of hydrochlorothiazide. 39 Moreover, chlorthalidone (plasma half-life: 60 hours 42 ) has a longer duration of action than hydrochlorothiazide (8 to 12 hours 42 ). In a randomized crossover trial with 8-week active-treatment periods, chlorthalidone (12.5 mg/d force-titrated to 25.0 mg/d) reduced the nighttime (Ϫ13.5 versus Ϫ6.4 mm Hg; Pϭ0.009) and, therefore, the 24-hour (Ϫ12.4 versus Ϫ7.4 mm Hg; Pϭ0.054) systolic blood pressure more than hydrochlorothiazide (25.0 mg force titrated to 50.0 mg). 40 Amlodipine has a longer duration of action than hydrochlorothiazide, so that blood pressure control is maintained even if 1 daily dose of amlodipine is omitted. 43 Thus, better blood pressure control over the whole day, not translated into a wide separation of the office blood pressure values after the initial titration period, might well explain the ACCOMPLISH results. 12 
Action in Diabetes and Vascular Disease: Preterax and Diamicron-Controlled Evaluation Trial
The primary objective of the Action in Diabetes and Vascular Disease: Preterax and Diamicron-Controlled Evaluation Trial (ADVANCE) [13] [14] [15] was to assess the effects of the routine administration of the combination of an ACE inhibitor and a diuretic on vascular events in patients with type 2 diabetes mellitus, irrespective of initial blood pressure levels or background therapies (Table 1) 14 The ADVANCE investigators concluded that the routine administration of a fixed combination of perindopril and indapamide to a broad range of patients with diabetes mellitus had reduced the risks of death and major macrovascular or microvascular complications, irrespective of the initial blood pressure level or ancillary treatment. 14 They extrapolated that if the benefits seen in their trial were applied to just half of the population with diabetes worldwide, Ͼ1 million deaths would be avoided over 5 years. For these reasons, they suggested considering such treatment routinely for patients with type 2 diabetes mellitus. These extrapolations certainly need to be tuned down. Indeed, most of the systolic blood pressure gradient seen in the ADVANCE trial was caused by an increase in systolic blood pressure among patients receiving placebo (from 137 to 140 mm Hg) rather than by a decrease in systolic blood pressure among those in the active-treatment group (from 137 to 136 mm Hg). What clinicians should, therefore, remember from the ADVANCE Trial 14 is not to stop antihypertensive therapy in diabetic patients but to intensify treatment until blood pressure control is reached. At entry, treatments were continued at the discretion of the responsible physician, with the exception of ACE inhibitors; participants taking an ACE inhibitor other than perindopril had this treatment withdrawn and were offered substitution with open-label perindopril at a dose of 2 or 4 mg/d. This procedure resulted in an increase in blood pressure at entry into the placebo group (see Figure 1 in Reference 14). Furthermore, ADVANCE did not prove that using combination therapy provides more benefit than the traditional approach of sequentially titrating, rotating, and combining antihypertensive agents of different classes. Finally, the CIs regarding the number of patient years of treatment required to prevent 1 event were wide.
Prevention Regimen for Effectively Avoiding
Second Strokes Trial 24 In an analysis only involving 1141 strokes that occurred 6 months after randomization, stroke recurrence decreased by 12% (95% CI: 1% to 22%; Pϭ0.04). 24 The PRoFESS investigators proposed that randomization of patients soon after the qualifying event might explain the null results of their trial. 24 However, the odds of stroke recurrence were similar in patients randomized within 10 days of the qualifying event (0.92; Pϭ0. 19 ) and in those randomized later (0.93; Pϭ0.18). The P value for interaction was 0.84. 24 In a 2ϫ2 design, all patients randomized to telmisartan or placebo were also allocated antiplatelet drugs. 26 Although the interaction between blood pressurelowering and antiplatelet treatment was nonsignificant (Pϭ0.35), the PRoFESS investigators suggested that background treatment, including statins in 47.4% of patients at entry, might have contributed to the disappointing results of the blood pressure-lowering arm of their trial. 24 The PRoFESS results 24 do not support the hypothesis 44 that ARBs might be particularly beneficial in the prevention of stroke, because unopposed stimulation of type 2 or type 4 angiotensin receptors in the ischemic brain might stimulate opening of collaterals 45 and increase neuronal resistance to anoxia. 46 
Ongoing Telmisartan Alone and in Combination With Ramipril Global
Endpoint Trial involved high-risk patients with coronary, peripheral arterial, or cerebrovascular disease or diabetic patients with end-organ damage ( Table 1 ). The trial had 2 objectives (Table 1) : to demonstrate the noninferiority of telmisartan compared with ramipril and to test whether the combination of telmisartan with ramipril was superior to ramipril alone.
Noninferiority of Telmisartan Versus Ramipril
Compared with ramipril, blood pressure was 0.9/0.6 mm Hg lower on telmisartan. The primary outcome occurred in 1412 patients in the ramipril group (16.5%) as compared with 1423 patients in the telmisartan group (16.7%), resulting in an HR of 1.01 (Pϭ0.83). 21 The upper boundary of the CI (1.09) was significantly lower than the predefined noninferiority boundary of 1.13 (Pϭ0.004; Figure 1 ). However, the lower boundary of the CI (0.94) indicated that telmisartan was not superior to ramipril. 21 Cough (1.1% versus 4.2%; PϽ0.001) and angioedema (0.1% versus 0.3%; Pϭ0.01) occurred less on telmisartan than ramipril, whereas the opposite was the case for hypotensive symptoms (2.6% versus 1.7%; PϽ0.001), but the rate of syncope was the same in the 2 groups (0.2%). Some experts advocate that noninferiority studies have no ethical justification, because they do not offer any advantage to patients and because they disregard patient interest in favor of commercial incentives to promote new marketable products. 47 Often the premise is that the new treatment might have an advantage, for instance, in terms of fewer adverse effects. That cough and angioedema would be less frequent on telmisartan than on ramipril was predictable and cannot justify the noninferiority approach. Furthermore, noninferiority means comparability within an arbitrary limit (⌬), indicating the tolerable inferiority of the experimental drug versus the standard. 47 There are no fixed rules to determine ⌬. In ONTARGET, 21 ⌬ was set at the 40th percentile (0.794) of treatment effects in trials comparing outcome on ACE inhibitors versus placebo. 1, 48 This boundary translated into an excess risk for placebo as compared with ramipril of 1.26. A margin of 1.13 (e [ln(1.26)ϫ0 .5] ) ensured that telmisartan retained at least half of the effect of ramipril, if the upper limit of the 1-sided 97.5% CI for the HR was less than this value. Consolidated Standards of Reporting Trials guidelines recommend 2-sided tests (Figure 1 ), 49 but a 1-sided 97.5% CI is equivalent to a 2-sided 95% CI. The significance level required to show noninferiority is open to question. 47, 49 
Telmisartan Plus Ramipril Versus Ramipril Alone
Compared with the ramipril group, blood pressure was 2.4 systolic and 1.4 mm Hg diastolic lower on telmisartan than on the combination. The primary outcome occurred in the combination-therapy group in 1386 patients (16.3%; HR versus ramipril alone: 0.99; Pϭ0.38). Hypotensive symptoms (4.8% versus 1.7%; PϽ0.001), syncope (0.3% versus 0.2%; Pϭ0.03), and renal dysfunction (13.5% versus 10.2%; PϽ0.001) occurred more frequently on combination therapy. 21 Total mortality was similar on telmisartan compared with ramipril (HR: 0.98; 95% CI: 0.90 to 1.07) but was slightly higher on combination therapy than on ramipril (HR: 1.07; 95% CI: 0.98 to 1.16). For the statement that analyses did not indicate significant differences with respect to any particular cause of death, no data were shown. 21 The main ONTARGET report 21 did not provide any information on the incidence of cancer, a predefined secondary outcome. However, in July 21 The primary composite outcome was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure. The main secondary outcome was death from cardiovascular causes, myocardial infarction, or stroke, which was used as the primary outcome in the HOPE Trial. 1 The 1-sided P values are for the comparison with the noninferiority margin. Reproduced with permission from Reference 21. B, Possible scenarios in noninferiority trials. The shaded area indicates the zone of inferiority. Error bars indicate 2-sided 95% CIs. A, If the CI lies wholly to the left of 0, the new treatment is superior. B and C, If the CI lies to the left of ⌬ and includes 0, the new treatment is noninferior but not shown to be superior. D, If the CI lies wholly to the left of ⌬ and wholly to the right of 0, the new treatment is noninferior in the sense already defined but it is also inferior in the sense that a null treatment difference is excluded. This case can result from having a too wide noninferiority margin. E, If the CI includes ⌬ and 0, the difference is nonsignificant, but the result regarding noninferiority is inconclusive. F, If the CI is wholly above ⌬, the new treatment is inferior. Reproduced with permission from Reference 49. 2009, in a document submitted to the Food and Drug Administration, Boehringer Ingelheim reported significantly higher HRs for malignancies on the combination of ramipril plus telmisartan than on ramipril alone (for details and reference, see the online Data Supplement).
Renal Outcomes and Left Ventricular Hypertrophy
The secondary renal outcome, dialysis or doubling of serum creatinine, was similar on telmisartan and ramipril (2.21% versus 2.03%; HR: 1.09; Pϭ0.42) but more frequent with combination therapy (2.49%; HR: 1.24; Pϭ0.038). 22 Estimated glomerular filtration rate declined less with ramipril compared with telmisartan or combination therapy (Ϫ2.82 versus Ϫ4.12 or Ϫ6.11 mL/min per 1.73 m 2 , respectively; PϽ0.0001). Compared with ramipril, the increase after randomization in the urinary albumin:creatinine ratio (expressed in mg/mmol/L) was less with telmisartan (ratio of last observed versus baseline urinary albumin:creatinine ratio: 1.32 versus 1.25; Pϭ0.033) or with combination therapy (1.32 versus 1.22; Pϭ0.0028). 22 In 23 165 ONTARGET patients with an ECG recorded at entry, 50 the prevalence of electrocardiographic left ventricular hypertrophy 51 at randomization was 12.5%. At 2 and 5 years of follow-up, left ventricular hypertrophy was slightly less frequent on telmisartan (odds ratio: 0.92; Pϭ0.07) and the combination (odds ratio: 0.93; Pϭ0.12) than on ramipril, but the between-group differences were not significant. A small substudy 52 of 287 selected patients who underwent MRI at baseline and at 2 years was confirmatory. Decrease in systolic blood pressure was a key determinant (PϽ0.0001) of the change in left ventricular mass. 52 
Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease
Patients screened for enrollment in ONTARGET who could not tolerate ACE inhibitors were eligible for randomization in the double-blind TRANSCEND Trial. 20 ,27
Stand-Alone Analysis of TRANSCEND
Compared with placebo, blood pressure was 4.0 mm Hg systolic and 2.2 mm Hg diastolic lower on telmisartan.
Hypotensive symptoms were more frequent on telmisartan than on placebo (0.98% versus 0.54%; Pϭ0.049). 27 The primary outcome was the same as in ONTARGET 21 and occurred in 465 patients (15.7%) of the telmisartan group and in 504 (17.0) of the placebo group (HR: 0.92; Pϭ0.22). 27 The composite secondary end point defined as in HOPE 1 occurred in 384 patients (13.0%) on telmisartan and in 440 patients (14.8%) randomized to placebo (HR: 0.76; 95% CI: 0.76 to 1.00). 27 The unadjusted P value was 0.048. With adjustment for multiple comparisons and the 87% overlap with the primary end point, it was 0.068. A post hoc analysis involved the primary composite end point as defined in ADVANCE. 13, 14 It occurred less frequently with telmisartan than with placebo (17.7% versus 19.8%; HR: 0.89; Pϭ0.049). 27 There was also a trend in favor of telmisartan in the prevention of myocardial infarction (3.9% versus 5.0%; HR: 0.79; Pϭ0.059).
The prevalence of electrocardiographic left ventricular hypertrophy 51 at entry in the 5343 TRANSCEND patients with a baseline ECG was 12.7%. 50 It was reduced by telmisartan (10.5% and 9.9% after 2 and 5 years) compared with placebo (12.7% and 12.8% after 2 and 5 years). The odds ratio for the total follow-up on telmisartan versus placebo was 0.79 (Pϭ0.0017). Achieved systolic blood pressure was the main determinant of the incidence or regression of left ventricular hypertrophy during follow-up. 50 
Combination of TRANSCEND and PRoFESS
In analyses prespecified 27 before the completion of PRoFESS 24 and TRANSCEND, 27 the TRANSCEND investigators pooled the results of these 2 trials (Table 2 ). In 26 258 randomized patients, the primary (Pϭ0.026) and secondary (Pϭ0.013) composite end points achieved borderline significance. In terms of absolute benefit, Ϸ1000 patients would have to be treated for 1 year with telmisartan to prevent 3 to 4 composite events. While stratifying by time (Table 2) , telmisartan had no effect within the first 6 months in both trials, but there was a clear benefit afterward. The PRoFESS report 24 proposed noncompliance with the proportional hazards assumption as the justification for this post hoc analysis, which was carried out after inspection of the Kaplan-Meier curves (see Figure 1 in Reference 24). All outcome analyses involved a time-to-event approach and included all randomized patients. 24 Thus, for the results from 6 months after randomization, patients who experienced an event earlier were censored at the time of the event and treated in the analysis as if no event had occurred. In PRoFESS alone, 24 this approach excluded a total of 673 patients, who experienced stroke recurrence within the first 6 months of randomization. In summary, combining the results of 2 selected trials does not comply with the principles of a systematic reviews. Significant P values in the time-stratified analyses were produced after having looked at the data. Finally, the PRoFESS 24 and TRANSCEND 27 results challenge the noninferiority results produced by ONTARGET 21 and suggest no more than a "modest" beneficial effect of telmisartan versus placebo on cardiovascular disease outcomes, if any at all. Moreover, the incidence of malignancies was 24% higher on telmisartan than placebo (7.3% versus 6.0%; see the online Data Supplement).
Clinical Implications
The clinical implications evolve mainly around 6 themes: generalizability of the results to the common patient with hypertension, benefit beyond blood pressure lowering in the protection of target organs, use of dual inhibition of the renin system with an ACE inhibitor and an ARB, and the prevention of stroke recurrence, coronary events, and new-onset diabetes mellitus.
Generalizability
To minimize the risk of null results at affordable costs, the recently published trials 12, 14, 21, 24, 27 not only needed to be large and simple but they also required high event rates. The researchers, therefore, recruited high-risk patients with diabetes mellitus, target organ damage, or a previous history of cardiovascular disease (Table 1) , whereas such patients were systematically excluded from the earlier generation of placebo-controlled trials 4 -7 and HYVET. 18 Table 1 lists the number of patients screened and randomized. The PRoFESS report provided no information on the number of patients screened. In ADVANCE, 13, 14 ONTARGET, 20 -22 and other trials of ACE inhibitors, 48 ACE-intolerant and noncompliant patients were systematically excluded. The patients enrolled in TRANSCEND 20, 27 were all ACE intolerant, and those noncompliant or experiencing adverse effects when challenged with a daily dose of 80 mg of telmisartan did not qualify for entry. Obviously, results are only applicable to patients with similar characteristics as those enrolled in the trials.
Beyond Blood Pressure
Above age 50 years, hypertension is the major cardiovascular risk factor. 53 Antihypertensive drugs reverse the risk by interfering with this risk indicator and must, therefore, confer benefit by lowering blood pressure. The relation between cardiovascular complications and blood pressure is continuous without threshold. 54, 55 Large-scale prospective observational studies 54, 55 and meta-regression analyses of randomized clinical trials demonstrated that small gradients in the systolic blood pressure can explain cardiovascular outcomes. 56, 57 This is not only true for stroke, 54, 55, 58 the complication most directly linked to blood pressure, but also for myocardial infarction, 54, 55, 58, 59 heart failure, 60 and left ventricular hypertrophy. 50, 52 In meta-regression analyses, 150 000 59 to 180 000 58 randomized patients, followed up for 3 to 5 years, were required to demonstrate 10% to 15% benefit beyond blood pressure lowering of newer antihypertensive drugs, such as CCBs and ACE inhibitors, in the prevention of stroke 58, 61 or myocardial infarction, 58, 59 respectively.
Using the meta-regression equations published in 2001, 56 we assessed to what extent recently reported risk ratios differed from the odds of benefit as predicted by gradients in systolic blood pressure (Table 3 ). The end points considered were cardiovascular mortality, cardiovascular events as defined in HOPE (cardiovascular death plus nonfatal stroke and nonfatal myocardial infarction 1 ), fatal plus nonfatal stroke (or stroke recurrence in PRoFESS 24 ), and fatal and nonfatal myocardial infarction. The trials evaluated were ACCOMPLISH, 12 ADVANCE, 14 PRoFESS, 24 ONTARGET, 21 and TRANSCEND. 27 In general, observed and predicted risks did not significantly differ (PՆ0.10), indicating that blood pressure gradients are sufficient to explain the outcome results. Table 3 lists differences (PϽ0.10) between predicted 56 and observed risks. 12,14,21,24, 27 The composite cardiovascular end point was reduced less than predicted in ADVANCE 14 and PRoFESS, 24 partly because of a shortfall in the reduction of stroke 14 or stroke recurrence. 24 In ONTARGET, 21 telmisartan did not reduce myocardial infarction, whereas in ACCOMPLISH 12 the decrease in the composite cardiovascular end point was greater than predicted on the basis of the reported small gradient in systolic blood pressure.
Dual Inhibition of the Renin System
In ONTARGET, 21, 22, 50, 52 dual inhibition of the renin system with an ACE inhibitor and an ARB, despite a 2.4-mm Hg reduction in systolic blood pressure, did not result in better outcomes but increased adverse events. The ONTARGET results 21, 22, 50, 52 were in line with the combined effects of an ARB plus an ACE inhibitor, as compared with an ACE inhibitor alone, in 4 previous trials of patients with left ventricular dysfunction. 62 The Combination of Treatment of Angiotensin-II Receptor Blocker and AngiotensinConverting-Enzyme Inhibitor in Non-Diabetic Renal Disease (COOPERATE) trial has recently been retracted from the published record and can no longer be used as evidence supporting dual inhibition of the renin system by the combination of an ACE inhibitor and an ARB (see the online Data Supplement). Whether these disappointing results would equally apply in terms of hard outcomes to the combination of an ARB with a renin inhibitor, such as aliskiren, 63 still remains to be established. For now, there is only positive evidence for blood pressure 31 and for soft intermediate end points in high-risk patients. 32, 34 Taken together, the currently available evidence suggests that dual inhibition of the renin system should only be sparingly and very carefully used in patients at high risk, in whom all drug combinations have been tried and who cannot be controlled by a single renin system inhibitor.
Prevention of Stroke Recurrence
For a better interpretation of the PRoFESS results, 24 we combined the results of 10 trials 24,64 -72 (11 groups of randomized patients), using methods described in detail elsewhere. 73 Overall, the odds ratio for the prevention of stroke recurrence by blood pressure-lowering therapy was 0.78 (Pϭ0.0007; Figure 2 ). There was significant heterogeneity between studies. The pooled odds ratio was 0.63 (PϽ0.0001) for trials involving diuretics as a component of therapy 64 -67 but only 0.93 (Pϭ0.086) for trials, 24, [67] [68] [69] [70] [71] in which the mainstay of treatment consisted of inhibition of the renin system by atenolol, 68, 69 perindopril, 67 ramipril, 70 candesartan, 71 or telmisartan. 24 The weighted 73 reduction in systolic blood pressure averaged 9.6 mm Hg in 4 studies of diuretics, 64 -67 4 .0 mm Hg in 6 studies of renin system inhibitors, 24,67-71 and 5.1 mm Hg in all studies combined 24,64 -72 ( Figure 2 ). In metaregression, the weighted correlation coefficient between the odds for stroke recurrence and the blood pressure reduction was Ϫ0.57 (Pϭ0.067). 73 The significant heterogeneity (PϽ0.0001) between diuretics and renin system inhibitors in the prevention of stroke recurrence might, therefore, be explained by the greater blood pressure reduction on treatments including diuretics.
In contrast to the recommendations in some guidelines, 37 the above results do not support the use of renin system inhibitors for the prevention of stroke recurrence. Furthermore, lowering blood pressure in patients with a history of stroke and a normal blood pressure cannot be recommended, because the published results are contradictory. In the PRoFESS Trial, 24 6822 patients with a systolic pressure at entry of Յ135 mm Hg had an odds ratio for stroke recurrence on active treatment versus placebo of 1.04 (95% CI: 0.87 to 1.25; Pϭ0. 63) . Similarly, in the TRANSCEND Trial, 27 1955 patients with a systolic pressure at entry of Յ133 mm Hg did not experience benefit from blood pressure-lowering therapy in terms of the primary and secondary composite end points. In contrast, the 913 Poststroke Antihypertensive Treatment Study patients, whose blood pressure at randomization was Ͻ140 mm Hg systolic and 90 mm Hg diastolic, had on treatment with indapamide a 50% lower risk of stroke recurrence (95% CI: Ϫ74 to Ϫ4; Pϭ0.03). 73 
Prevention of Coronary Events
The TRANSCEND investigators claimed 27 that the results of their trial, along with those of ONTARGET, should help to dispel concerns 74 that ARBs might not reduce myocardial infarction. The results of TRANSCEND (HR versus placebo: 0.79; 95% CI: 0.62 to 1.01; Pϭ0.059) 27 and those of ONTARGET 21 (HR versus ramipril: 1.07; 95% CI: 0.94 to 1.22; estimated Pϭ0.31; see also Table 3 ) do not support this assertion. Several trials suggested that ARBs might protect less against coronary complications than placebo, 75 a ␤-blocker (atenolol), 2 diuretics, 71 or CCBs (amlodipine). 76, 77 A systematic review of 26 trials compared ACE inhibitors and ARBs with placebo or other drug classes. 59 The prevention of myocardial infarction depended on the reduction in blood pressure for both types of renin system inhibitors, but ACE inhibitors apparently had a blood pressure-independent effect on the prevention of myocardial infarction, which was not present for ARBs (9% versus Ϫ8%; Pϭ0.002). 59 To our knowledge, a head-to-head comparison of ACE inhibitors versus ARBs for the primary prevention of myocardial infarction is The table includes specific outcomes, for which the significance of the difference between observed vs predicted odds ratios was Ͻ0.10. End points tested included cardiovascular mortality (CVM) and cardiovascular events (CVE) consisting of the composite of cardiovascular mortality, nonfatal stroke plus nonfatal myocardial infarction (primary end point in the HOPE Trial 1 ), fatal plus nonfatal stroke or stroke recurrence (CVA), and fatal plus nonfatal myocardial infarction (MI). Trial acronyms are explained in the text. ONTARGET/telmisartan and ONTARGET/combination refer to the comparison of ramipril (reference) with telmisartan alone or with the combination of ramipril plus telmisartan.
*⌬SBP is the difference in systolic pressure (experimental minus control group) as defined in Table 1 . †Data show the observed risk (experimental/control) with 95% CI. ‡Data show the odds ratio (95% CI) predicted by metaregression. 56 §Data show significance of the difference between observed and predicted odds ratios.
currently unavailable. In the absence of intolerance, ACE inhibitors should, therefore, remain the preferred renin system inhibitor for cardiovascular protection in hypertensive or high-risk patients.
Prevention of Diabetes Mellitus
A network meta-analysis evaluated the incidence of newonset diabetes mellitus according to the drug class used to initiate blood pressure-lowering therapy ( Figure 3 ). 78 With diuretics as the comparator, the odds ratios were 0. (Figure 3 ), Ϸ1000 patients would have to be treated for 1 year with the newer agents to avoid Ϸ6 iatrogenic cases of diabetes mellitus. Important caveats in the interpretation of this estimate are that, in most trials included in the network meta-analysis, new-onset diabetes mellitus was not a predefined end point; that follow-up was relatively short; and that, in some trials, the comparator was a diuretic 41 or ␤-blocker. 76 In PRoFESS 24 and TRANSCEND, 27 diabetes was a predefined secondary end point, and the comparator was placebo. In PRoFESS, 24 the number of patients who had new-onset diabetes after randomization was 125 of 7360 (1.70%) in the telmisartan group, as compared with 151 of Figure 2 . Effects of blood pressure lowering on fatal and nonfatal recurrent stroke. Solid squares represent the odds ratios in individual trials and have a size proportional to the inverse of the variance. Horizontal lines and diamonds denote the 95% CIs for individual trials and summary statistics, respectively. Pooled estimates were computed from a random-effect model in case of significant heterogeneity and otherwise from fixed-effect models. The vertical dotted line marks the position of the point estimate of the pooled effect size for all trials combined. TIA indicates transient ischemic attack. BP and ⌬BP stand for the average blood pressure at randomization and the difference in achieved blood pressure between randomized groups. The individual studies were as follows: Carter's trial 64 ; the Hypertension-Stroke Cooperative Study (HSCG) 65 ; the Dutch TIA Trial 68 ; the Tenormin After Stroke Trial (TEST) 69 ; the Poststroke Antihypertensive Treatment Study (PATS) 66 ; the Perindopril Protection Against Recurrent Stroke Study 67 -Monotherapy (PROGRESS/Per) and combined therapy (PROGRESS/Com) arms; the HOPE study 70 ; Study on Cognition and Prognosis in the Elderly (SCOPE) 71 ; the Felodipine Event Reduction Study (FEVER) 72 ; and the PRoFESS trial. 24 For Carter's trial, 64 the blood pressure at randomization was estimated by adding 10 and 5 mm Hg to the qualifying systolic and diastolic levels at entry. Reproduced with permission from Reference 73. 
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Perspectives
Without usable and accessible reports, research cannot help clinicians and their patients. 83 Consolidated Standards of Reporting Trials experts 49, 84 might reflect on new guidelines on how changes in a targeted risk factor should be reported in relation to the outcome of interest. In particular, how should blood pressure gradients be reported in trials claiming organ protection beyond blood pressure lowering. Should it be the baseline-adjusted between-group difference between the measurement at the last available visit or before an event, as in the Losartan Intervention for Endpoint Reduction Trial, 2 or should all blood pressure measurements in each patients be accounted for? Blood pressure readings taken shortly before an event are likely to be influenced by the upcoming end point. 85 How can we avoid the fact that blood pressure gradients early in a clinical trial are concealed by overscaling of graphics? 2, 12 Figure 3 in the Valsartan Antihypertensive Long-Term Use Evaluation report 80 or Figure 2 in the ADVANCE article 14 provide examples of how full information can be provided. None of the beyond blood pressure trials reported on the quality of the blood pressure measurements. Digit and number preference in the blood pressure readings 86, 87 were monitored in HYVET 18 and led to the closure of centers not keeping up minimal quality standards. Development and application of more accurate blood pressure measurement technologies, for example, observer bias-free measurements with minimized whitecoat effect in the hospital environment 88 or selfmeasurement combined with telemonitoring, 89 might be envisaged in future trial designs. With regard to the interpretation of clinical trials, Consolidated Standards of Reporting Trials guidelines 84 (http://www.consort-statement.org) require that the results be discussed taking into account possible sources of bias or imprecision, the dangers associated with the multiplicity of outcomes, and the generalizability (external validity). Biases arise when different stakeholders, including the manufacturers of marketable drugs, assign their own values to the design and interpretation 90 of clinical trials. Sponsors and investigators tend to look for what they would like to see. 91 Overinterpretation of nonsignificant or marginal 27 P values in large trials with overlapping end points, generalizing beyond selection criteria, 12, 14, 21, 24, 27 and labeling nonsignificant treatment effects as modest 27 do necessarily comply with Consolidated Standards of Reporting Trials guidelines. 84 Clinicians might read such small benefits as effects sufficiently large to change their prescriptions, 90 so that patients might not receive the best possible treatment. Recently, Califf et al 92 made recommendations for how to increase transparency and how to reconcile commercial with societal interests. Among other things, they suggested that long-term efforts should be made to house master databases of clinical trials and their statistical exploitation at nonprofit institutions, for which the primary mission is acting for the common good rather than returning value to shareholders. 92 Perhaps the time has come to revise the concept of large simple trials 3 and to pursue research questions that serve patient care more than showing noninferiority or highlighting the ancillary qualities of marketable antihypertensive drugs.
Sources of Funding
None. were not running independently from each other, but have to be viewed as 2 complementary studies within a single research program. 1 The primary objectives of ONTARGET [1] [2] [3] were to determine whether the combination of the angiotensin receptor blocker (ARB) telmisartan plus the angiotensinconverting enzyme (ACE) inhibitor ramipril was more effective in the prevention of cardiovascular and renal complications than ramipril alone, and to test whether telmisartan was at least as effective as ramipril. This explains the dual entries for ONTARGET in Table S1 .
Review of the Evidence
HYVET
The Hypertension in the Very Elderly Trial (HYVET) was a primary prevention trial, set up with the goal to extend the indication for blood pressure lowering treatment to very elderly hypertensive patients (≥80 years), of whom only 11.8% had a history of previous cardiovascular disease. [5] [6] [7] [8] The patients were randomized to the diuretic indapamide (sustained release, 1.5 mg/d) or matching placebo. If necessary to achieve a target blood pressure below 150 mm Hg systolic and 80 mm Hg diastolic, the ACE inhibitor perindopril (2 or 4 mg/d), or matching placebo, was added. The primary end point was fatal plus nonfatal stroke. At 2 years, the blood pressure was on average 15.0 mm Hg systolic and 6.1 mm Hg diastolic lower on active treatment than on placebo. 7 In the intention-to-treat analysis, blood pressure lowering reduced the incidence of complications: fatal combined with nonfatal stroke by 30% (95% confidence interval [CI]: −1 to 51; P=0.06), fatal stroke by 39% (CI: 1 to 62; P=0.05), all-cause mortality by 21% (CI: 4 to 35; P=0.02), cardiovascular mortality by 23% (CI: −1 to 40; P=0.06), and heart failure by 64% (CI: 42 to 78; P<0.001). To prevent one death or one stroke, 40 and 94 very elderly had to be treated for 2 years. 7
ACCOMPLISH
The main research question of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension Trial (ACCOMPLISH) [9] [10] [11] [12] [13] was whether treatment with the combination of an ACE inhibitor and a dihydropyridine calcium-channel blocker (CCB) would be more effective in reducing cardiovascular events than treatment with an ACE inhibitor plus a thiazide. All 11,506 patients (>55 years 11 ) had hypertension and were at high cardiovascular risk, because of a history of hospitalized unstable angina (11.6%), myocardial infarction (23.5%), coronary revascularization (35.8%), stroke (13.0%), renal disease (6.1%), an estimated glomerular filtration of less than 60 mL/min (18.1%), left ventricular hypertrophy (13.2%), or diabetes mellitus (60.4%). Hypertension was a systolic blood pressure of at least 160 mm Hg or the use of antihypertensive drugs.
Patients began treatment with either a combination of 20 mg of benazepril and 5 mg of amlodipine or a combination of 20 mg of benazepril and 12.5 mg of hydrochlorothiazide, once daily. In both treatment groups, 1 month after randomization, the daily dose of benazepril was doubled to 40 mg. Thereafter, investigators could increase the amlodipine dose to 10 mg/d and increase the hydrochlorothiazide dose to 25 mg/d, if necessary, to attain a target blood pressure of less than 140/90 mm Hg (or less than 130/80 mm Hg in patients with diabetes or renal disease). Mean blood pressure after dose adjustment was 131.6/73.3 mm Hg in the benazepril-amlodipine group (n=5463) and 132.5/74.4 mm Hg in the benazepril-hydrochlorothiazide group (n=5474). The mean difference in blood pressure between the 2 groups was 0.9 mm Hg systolic and 1.1 mm Hg diastolic (P<0.001 for both systolic and diastolic blood pressures). Blood pressure control was attained in 75.4% of patients of the benazeprilamlodipine group and in 72.4% of patients of the benazepril-hydrochlorothiazide group.
The primary end point was the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization. There were 552 primary outcome events in the benazepril-amlodipine group (9.6%) and 679 in the benazepril-hydrochlorothiazide group (11.8%), representing an absolute risk reduction with benazepril-amlodipine therapy of 2.2% and a relative risk reduction of 19.6% (hazard ratio 
ADVANCE
The primary objective of the Action in Diabetes and Vascular disease: preterAx and diamicronNControlled Evaluation trial (ADVANCE) was to assess the effects of the routine administration of the combination of an ACE inhibitor and a diuretic on vascular events in patients with type-2 diabetes, irrespective of the initial blood pressure levels or the use of other blood pressure lowering drugs (Table  S1 ). 15, 16 Potentially eligible participants entered a 6-week prerandomization period, during which they received once daily a fixed combination tablet containing 2 mg perindopril and 0.625 mg indapamide. All other treatments were continued at the discretion of the responsible physician, with the exception of ACE inhibitors; participants taking an ACE inhibitor other than perindopril had this treatment withdrawn and were offered substitution with open-label perindopril at a dose of 2 mg/d or 4 mg/d. Patients who adhered to, and tolerated, the open-label study medication were randomized in a double-blind fashion to the combination of 2 mg perindopril plus 0.625 mg indapamide or matching placebo. The dose of the study medication was doubled 3 months after randomization. The primary end points were composites of major macrovascular and microvascular events. The macrovascular and microvascular composite end points were analyzed jointly and separately. Major macrovascular events were cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Major microvascular events were new or worsening nephropathy (development of macroalbuminuria, doubling of serum creatinine to a level of at least 200 μmol/L, need for renal replacement therapy, or death due to renal disease) or retinopathy (development of proliferative retinopathy, macular edema, diabetes-related blindness, or the need for retinal photocoagulation therapy). 16 The mean duration of follow-up was 4.3 years (Table S1 ). The mean blood pressure at entry was 145 mm Hg systolic and 81 mm Hg diastolic. The entry blood pressure was less than 140 mm Hg systolic and 90 mm Hg diastolic in 41.0% of patients. Compared with patients assigned placebo, those assigned active therapy had a lower blood pressure during follow-up. The difference averaged 5.6 mm Hg systolic and 2.2 mm Hg diastolic. There were 861 primary outcome events (macrovascular plus microvascular) in the active treatment group (15.5%) and 938 in the placebo group (16.8%). The HR for active vs placebo treatment was 0.91 (CI: 0.83 to 1.00; P=0.04). The separate reductions in macrovascular and microvascular events were similar, but on their own did not reach significance. The HR was 0.92 (CI: 0.81 to 1.04; P=0.16) for macrovascular end points and 0.91 (CI: 0.80 to 1.04; P=0.16) for microvascular events. In the active treatment group, 211 cardiovascular deaths occurred (3.8 %) and in the placebo group 257 (4.6%), resulting in a HR of 0.82 in favor of active treatment (CI: 0.68 to 0.98; P=0.03). With respect to all-cause mortality, 408 (7.3%) and 471 (8.5%) deaths occurred on active treatment and placebo, respectively, resulting in a HR of 0.86 (CI: 0.75 to 0.98; P=0.03). On active treatment, as compared with placebo, there was a reduced risk of coronary events (468 vs 535; 8.4% vs 9.6%; HR: 0.86; CI: 0.76 to 0.98; P=0.02). According to the ADVANCE investigators, there was no evidence that the effects of the study treatment differed by initial blood pressure level or concomitant use of other treatments at baseline. In terms of absolute benefit, the number of patients to be treated for 5 years amounted to 66 (CI: 34 to 1068), 79 (CI: 43 to 483), or 75 (CI: 41 to 453) to prevent one vascular event, one death, or one coronary accident, respectively. 16 
PRoFESS
The Prevention Regimen For Effectively avoiding Second Strokes trial (PRoFESS) [17] [18] [19] [20] compared in a double-blind fashion telmisartan (80 mg/d) with placebo, given on top of usual treatment (Table S1) . PRoFESS involved 20,332 patients who recently had an ischemic stroke. The time from stroke to randomization was 10 days or less among 8087 patients (39.8%), 11 to 30 days among 5887 patients (29.0%), and more than 30 days among 6314 patients (31.1%). The median interval was 15 days. To be eligible patients had to have at least 2 of the following risk factors: diabetes mellitus, hypertension (blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic), smoking, a body mass index larger than 30 kg/m 2 , hyperlipidemia, previous vascular disease, or target organ damage. 17 The primary outcome was stroke recurrence. Secondary outcomes were major cardiovascular events (death from cardiovascular causes, recurrent stroke, myocardial infarction, or new or worsening heart failure), and new-onset diabetes.
During a mean follow-up of 2.5 years, blood pressure was 3.8 mm Hg systolic and 2.0 mm Hg diastolic lower on telmisartan than on placebo (Table S1 ). A total of 880 patients (8.7%) in the telmisartan group and 934 patients (9.2%) in the placebo group had a subsequent stroke (HR for telmisartan: 0.95; CI: 0.86 to 1.04; P=0.23). 18 Major cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and 1463 patients (14.4%) in the placebo group (HR: 0.94; CI: 0.87 to 1.01; P=0.11). The number of patients who had new-onset diabetes after randomization was 125 of 7360 (1.70%) in the telmisartan group, as compared with 151 of 7283 (2.08%) in the placebo group (HR: 0.82; CI: 0.65 to 1.04; P=0.10). 18 In an analysis only involving 1141 strokes that occurred 6 months after randomization, stroke recurrence decreased by 12% (CI: 1% to 22%; P=0.04). 18 Furthermore, the odds of stroke recurrence were similar in patients randomized within 10 days of the qualifying event (0.92; CI: 0.81 to 1.04; n=8087; P=0. 19 ) and in those randomized later (0.93; CI: 0.84 to 1.03; n=12,201; P=0.18). The P-value for interaction was 0.84. 18 At entry, 47.4% of PRoFESS patients were taking statins. In a 2 × 2 design, all patients randomized to telmisartan or placebo were also allocated antiplatelet drugs (25 mg aspirin plus 200 mg extended-release dipyridamole, twice daily, vs 75 mg clopidogrel, once daily). 20 The interaction between blood pressure lowering and antiplatelet treatment was nonsignificant (P=0.35).
ONTARGET
The ONTARGET trial 1-3 involved high-risk patients with coronary, peripheral arterial or cerebrovascular disease or diabetic patients with target organ damage (Table S1 ). The primary outcome in ONTARGET [1] [2] [3] was the composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure. The main secondary outcome was a composite of death from cardiovascular causes, myocardial infarction or stroke, which had been the primary end point in the HOPE trial. 14 The ONTARGET trial had 2 objectives (Table S1) : to demonstrate the noninferiority of telmisartan compared with ramipril and to test whether the combination of telmisartan with ramipril was superior to ramipril alone. After a 3-week, single-blind run-in period, patients underwent double-blind randomization, with 8576 assigned to receive 10 mg of ramipril per day, 8542 assigned to receive 80 mg of telmisartan per day, and 8502 assigned to receive both drugs (combination therapy). 2 A high proportion of the 25,620 randomized patients had previously received statins (61.6% at baseline, changing to 70.6% by the end of the study), antiplatelet therapy (from 80.9% to 77.5%), β-blockers (from 56.9% to 56.9%), or diuretics (from 28.0% to 32.5%). 2 Median follow-up was 56 months (Table S1 ). 2 The blood pressure at entry averaged 142/81 mm Hg. Compared with the ramipril group, blood pressure was 0.9/0.6 mm Hg lower on telmisartan and 2.4/1.4 mm Hg lower on the combination. The primary outcome occurred in 1412 patients in the ramipril group (16.5%), as compared with 1423 patients in the telmisartan group (16.7%; HR: 1.01; CI: 0.94 to 1.09). 2 The upper boundary of the CI (1.09) for the relative risk of the primary outcome in the telmisartan group as compared with the ramipril group was significantly lower than the predefined noninferiority boundary of 1.13 (P=0.004). However, the lower boundary of the CI (0.94) indicated that telmisartan was not superior to ramipril. 2 As compared with the ramipril group, the telmisartan group had lower rates of cough (1.1% vs 4.2%; P<0.001) and angioedema (0.1% vs 0.3%; P=0.01) and a higher rate of hypotensive symptoms (2.6% vs 1.7%; P<0.001), but the rate of syncope was the same in the 2 groups (0.2%).
In the combination therapy group, the primary outcome occurred in 1386 patients (16.3%; HR: 0.99; CI: 0.92 to 1.07). On the combination, as compared with ramipril, there was an increased risk of hypotensive symptoms (4.8% vs 1.7%; P<0.001), syncope (0.3% vs 0.2%; P=0.03), and renal dysfunction (13.5% vs 10.2%; P<0.001). 2 The results for the main secondary outcome, defined as in HOPE, 14 were similar to those of the primary outcome. Total mortality was similar on telmisartan compared with ramipril (989 vs 1014 deaths; HR: 0.98; CI: 0.90 to 1.07), but higher in the combination therapy group than in the ramipril group (1065 vs 1014 deaths; HR: 1.07; CI: 0.98 to 1.16), but the difference did not reach statistical significance (P=0.11).
The secondary renal outcome, dialysis or doubling of serum creatinine, was similar on telmisartan and ramipril (2.21% vs 2.03%; HR: 1.09; CI: 0.89 to 1.34; P=0. 42) , but more frequent with combination therapy (2.49%; HR: 1.24; CI: 1.01 to 1.51; P=0.038). 3 Estimated glomerular filtration rate declined less with ramipril compared with telmisartan or combination therapy (-2.82 vs −4.12 or −6.11 ml/min/1.73 m 2 , respectively; P<0.0001). Compared with ramipril, the increase after randomization in the urinary albumin:creatinine ratio (UACR), expressed in mg/mmol/L, was less with telmisartan (ratio of last observed vs baseline UACR: 1.32 vs 1.25; P=0.033) or with combination therapy (1.32 vs 1.22; P=0.0028). 3 In ONTARGET 21 and TRANSCEND, 4 electrocardiographic left ventricular hypertrophy (yes/no) was based on one or both of the following criteria: (1) sum of the R wave in lead aVL and the S wave in lead V 3 less than 2.0 mV in women or 2.4 mV in men; or (2) strain pattern in I, II, aVL, or V 2 to V 6 . A strain pattern was considered to be present, if there was ST-segment depression of at least 0.5 mm and an inverted T wave in any lead in the direction opposite the polarity of the QRS complex. 21 This definition of electrocardiographic left ventricular hypertrophy has been validated in terms of outcome. 22 In ONTARGET patients with an electrocardiogram recorded at entry, the prevalence of left ventricular hypertrophy at randomization to ramipril (n=7781), telmisartan (n=7773) or the combination (n=7651) was 12.5%, 12.5% and 12.4%, respectively. 21 The prevalence of left ventricular hypertrophy decreased (P<0.001 for all) on ramipril (10.8% and 10.5% at 2 and 5 years), telmisartan (10.0% and 9.7%), and the combination (9.9% and 10.2%). Left ventricular hypertrophy showed a nonsignificant trend to be less frequent with telmisartan than with ramipril (odds ratio [OR]: 0.92; CI: 0.83 to 1.01; P=0.07). The odds of left ventricular hypertrophy during follow-up were also nonsignificantly lower with the combination compared with ramipril (OR: 0.93; CI: 0.84 to 1.02; P=0.12). There was no differences in the odds of left ventricular hypertrophy between the telmisartan group and the combination therapy group (OR: 1.01; CI: 0.91 to 1.12). 21 A small substudy 23 involved 287 patients who underwent MRI at baseline and after 2 years (90, 100, and 97 patients in the ramipril, telmisartan, and combination therapy groups, respectively). The results 23 confirmed those of the electrocardiographic study. 21 At 2 years, left ventricular mass showed average decreases of 4.8% on ramipril, 3.3% on telmisartan, and 5.8% on combination therapy (P<0.0001 for all). 23 There were no significant differences among treatment groups in change in left ventricular mass or in any other cardiac measurement on MRI, except for left ventricular mass indexed to height 2.7 for combination therapy vs telmisartan (P=0.04). When the 3 treatment groups were combined, the key determinants of the decrease in left ventricular mass were the baseline value (slope: 0.126; P<0.0001), decrease in systolic blood pressure (slope: 0.039 g/m 2.7 /mm Hg; P<0.0001), and history of hypertension (P=0.03). 23 In July of 2009, Boehringer Ingelheim presented a detailed briefing document about telmisartan to the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration. 24 In this document, the sponsor noted imbalances in malignancies in both ONTARGET 21 and TRANSCEND. 4 In ONTARGET, 21 the hazard for malignancies was significantly higher for the combination of telmisartan plus ramipril than ramipril alone, regardless of the presence of malignancies at baseline (824 [ 
TRANSCEND
Patients screened for enrollment in ONTARGET, who could not tolerate ACE inhibitors (n=6666), entered a 3-week single-blind run-in period involving placebo for 1 week followed by telmisartan 80 mg/d. 4 Of those patients who terminated the run-in period without showing poor compliance or sideeffects, 5926 (88.9%) were randomized in a double-blind fashion to receive telmisartan 80 mg/d (n=2954) or placebo (n=2972).
Median follow-up was 56 months (Table S1 ). The blood pressure at entry averaged 141/70 mm Hg. Compared with placebo, blood pressure was 4.0 mm Hg systolic and 2.2 mm Hg diastolic lower on telmisartan. Hypotensive symptoms were more frequent on telmisartan than on placebo (0.98% vs 0.54%; P=0.049). 4 The primary outcome was the same as in ONTARGET. 2 It occurred in 465 patients (15.7%) of the telmisartan group and in 504 (17.0%) of the placebo group (HR: 0.92; CI: 0.81 to 1.05; P=0.22). 4 The composite secondary end point, defined as in HOPE, 14 occurred in 384 patients (13.0%) on telmisartan and in 440 patients (14.8%) randomized to placebo (HR: 0.76; CI: 0.76 to 1.00). 4 The unadjusted P-value was 0.048. With adjustment for multiple comparisons and the 87% overlap with the primary end point, it was 0.068. In the telmisartan group, 894 patients (30.3%) were hospitalized for a cardiovascular reason, compared with 980 (33.0%) on placebo (HR: 0.92; CI: 0.85 to 0.99; P=0.025). 4 A post-hoc analysis involved the primary composite end point, as defined in ADVANCE, 15 78) were similar on telmisartan and placebo. 4 New-onset diabetes mellitus was a predefined secondary outcome. 4 The number of patients who had a clinical diagnosis of new-onset diabetes was 209 of 1895 (11.0%) in the telmisartan group, as compared with 245 of 1913 (12.8%) in the placebo group (HR: 0.85; CI: 0.71 to 1.02; P=0.081).
The prevalence of electrocardiographic left ventricular hypertrophy 22 at entry in TRANSCEND was 12.7%. 21 It was reduced by telmisartan (n=2688; 10.5% and 9.9% after 2 and 5 years) compared with placebo (n=2655; 12.7% and 12.8% after 2 and 5 years). The OR for the total follow-up on telmisartan vs placebo was 0.79 (CI: 0.68 to 0.91; P=0.0017). New-onset left ventricular hypertrophy occurred less frequently with telmisartan as compared with placebo (OR: 0.63; CI: 0.51 to 0.79; P=0.0001). The average reduction in systolic blood pressure from entry to follow-up was greater in the patients without than in those with incident left ventricular hypertrophy (4.8 vs 1.8 mm Hg; P<0.0001). In the TRANSCEND patients with electrocardiographic left ventricular hypertrophy at randomization, the frequency of regression was similar on telmisartan and placebo (OR: 0.91; CI: 0.70 to 1.19; P=0.49). 21 In this subgroup, the reduction in systolic blood pressure at follow-up was greater in patients with regression than in those with persistent left ventricular hypertrophy (6.8 vs 3.9 mm Hg; P<0.0001).
In TRANSCEND, 4 the risk of malignancies in patients without cancer at baseline (95% of all patients) was significantly higher for telmisartan than placebo (206 [7.3%] 25 Side effects occurred with similar frequencies in the 3 randomized groups. According to the COOPERATE investigators, 25 combination treatment safely slowed progression of nondiabetic renal disease compared with monotherapy. However, while attempting to include the COOPERATE data in a meta-analysis, Kunz and colleagues 26 identified several inconsistencies in the published report. 25 An institutional review board then audited the COOPERATE results. The Lancet Editors recently reviewed the conclusions of this investigation and concluded that the COOPERATE trial had to be retracted from the published literature. 27 Abbreviations: HCTZ = hydrochlorothiazide; RRR = relative risk reduction; SBP/DBP = systolic/diastolic blood pressure; …, the information was unavailable in published reports. End points: A, hospitalized angina pectoris; CVM, cardiovascular mortality; FS, fatal stroke; HF, hospitalized heart failure; MI, nonfatal myocardial infarction; MICVE, microvascular events; S, nonfatal stroke; RCA, resuscitated cardiac arrest. Major MICVE in ADVANCE were new or worsening nephropathy (development
